Retrieve available abstracts of 77 articles: HTML format
Single Articles
June 2025
XHAFERI A, Bino S, Daja R, Vasili A, et al Sociodemographic and Occupational Factors Associated With Coronavirus Disease
2019 Vaccine and Influenza Vaccine Uptake Among Healthcare Workers, in Albania,
2022-2023: A Multicenter Study.
Clin Infect Dis. 2025 Jun 3:ciaf202. doi: 10.1093. PubMedAbstract available
May 2025
CHUMAKOV K, Plotkin SA Inactivated Polio Vaccine Must Be an Essential Part of Polio Eradication.
Clin Infect Dis. 2025 May 21:ciaf215. doi: 10.1093. PubMed
MEHMOOD N, Alam MM, Arshad Y, Akhtar R, et al Clinical and Epidemiological Investigation of Vaccine-Derived Poliovirus Type 2
Outbreak in Pakistan During 2019-2021.
Clin Infect Dis. 2025 May 21:ciaf151. doi: 10.1093. PubMedAbstract available
KU JH, Gu YM, Hoke CF, Tseng HF, et al Screening and vaccination rates for tetanus, hepatitis A, and hepatitis B among
individuals with substance use disorders who are hospitalized in an integrated
U.S. health system.
Clin Infect Dis. 2025 May 20:ciaf251. doi: 10.1093. PubMedAbstract available
REGAN JJ, Wang Z, Phares CR The Effect of Live-Virus Vaccines on Tests for Tuberculosis Infection During the
US Immigration Medical Examination: Are Vaccines Causing False-Negative Results?
Clin Infect Dis. 2025 May 15:ciaf129. doi: 10.1093. PubMedAbstract available
KONOPNICKI D, Gilles C, Manigart Y, Barlow P, et al Immunogenicity and safety of two versus three doses of 9-valent vaccine against
Human papillomavirus (HPV) in women with HIV: the Papillon randomized trial.
Clin Infect Dis. 2025 May 13:ciaf241. doi: 10.1093. PubMedAbstract available
AMARIN JZ, Toepfer AP, Spieker AJ, Hayek H, et al Respiratory Syncytial Virus Co-Detection With Other Respiratory Viruses Is Not
Significantly Associated With Worse Clinical Outcomes Among Children Aged <2
Years: New Vaccine Surveillance Network, 2016-2020.
Clin Infect Dis. 2025 May 9:ciaf194. doi: 10.1093. PubMedAbstract available
April 2025
TORCEL-PAGNON L, Coudeville L, Harris RC, Chaves SS, et al The Impact of Influenza on US Working-Age Adults: Exploring the Benefits of the
Recombinant Influenza Vaccine.
Clin Infect Dis. 2025 Apr 17:ciaf200. doi: 10.1093. PubMedAbstract available
MESSCHENDORP AL, Zaeck LM, Bouwmans P, van den Broek DAJ, et al Replacing Mycophenolate Mofetil by Everolimus in Kidney Transplant Recipients to
Increase Vaccine Immunogenicity: Results of a Randomized Controlled Trial.
Clin Infect Dis. 2025 Apr 15:ciaf107. doi: 10.1093. PubMedAbstract available
FOX A, Sanchez-Ovando S, Carolan L, Hadiprodjo AJ, et al Enhanced Influenza Vaccines Extend A(H3N2) Antibody Reactivity in Older Adults
but Prior Vaccination Effects Persist.
Clin Infect Dis. 2025 Apr 3:ciaf060. doi: 10.1093. PubMedAbstract available
March 2025
KELLY JD, Hoggatt KJ, Lo NC, Leonard S, et al Annual variant-targeted vaccination to prevent severe COVID-19 disease in cohorts
with vaccine-derived and hybrid immunity.
Clin Infect Dis. 2025 Mar 14:ciaf124. doi: 10.1093. PubMedAbstract available
February 2025
DAVIDO B, Kharkhordine M Enhancing Influenza Vaccination for Adults Aged 50-64: Addressing Moderate
Vaccine Efficacy.
Clin Infect Dis. 2025 Feb 20:ciaf070. doi: 10.1093. PubMed
WALSH EE, Eiras D, Woodside J, Jiang Q, et al Efficacy, Immunogenicity, and Safety of the Bivalent RSV Prefusion F (RSVpreF)
Vaccine in Older Adults Over 2 RSV Seasons.
Clin Infect Dis. 2025 Feb 10:ciaf061. doi: 10.1093. PubMedAbstract available
January 2025
BANOONI P, Gonik B, Epalza C, Reyes O, et al Efficacy, immunogenicity, and safety of an investigational maternal respiratory
syncytial virus prefusion F protein-based vaccine.
Clin Infect Dis. 2025 Jan 29:ciaf033. doi: 10.1093. PubMedAbstract available
Correction to: Incidence of Tetanus and Diphtheria in Relation to Adult
Vaccination Schedules.
Clin Infect Dis. 2025 Jan 15:ciaf014. doi: 10.1093. PubMed
CHUNG JR, Price AM, Zimmerman RK, Moehling Geffel K, et al Influenza vaccine effectiveness against medically attended outpatient illness,
United States, 2023-24 season.
Clin Infect Dis. 2025 Jan 6:ciae658. doi: 10.1093. PubMedAbstract available
December 2024
BIRABAHARAN M, Johns ST, Kaelber DC, Martin TCS, et al Atrial Fibrillation after RSV Vaccination Among Older Adults.
Clin Infect Dis. 2024 Dec 26:ciae649. doi: 10.1093. PubMedAbstract available
NOLAN T, Bhusal C, Hoberman A, Llapur CJ, et al Immunogenicity, Reactogenicity, and Safety of a Pentavalent Meningococcal ABCWY
Vaccine in Adolescents and Young Adults who had Previously Received a
Meningococcal ACWY Vaccine: Phase 3, Randomized, Controlled Clinical Study.
Clin Infect Dis. 2024 Dec 26:ciae622. doi: 10.1093. PubMedAbstract available
PLOTKIN SA, Shapiro ED The Current and Future State of Vaccines for Lyme Disease.
Clin Infect Dis. 2024 Dec 23:ciae639. doi: 10.1093. PubMedAbstract available
WANG X, Patel C, Giles ML, Burns P, et al Glucocorticoid dosing and implications for vaccination: Evolution of global
definitions.
Clin Infect Dis. 2024 Dec 18:ciae613. doi: 10.1093. PubMedAbstract available
DAGAN R, van der Beek BA Immune Response to the 13-Valent Pneumococcal Conjugate Vaccine is Reduced in
Infants Immunized during the Respiratory Viral Season.
Clin Infect Dis. 2024 Dec 17:ciae619. doi: 10.1093. PubMedAbstract available
WEE LE, Lim JT, Goel M, Malek MIA, et al Bivalent boosters and risk of post-acute sequelae following vaccine-breakthrough
SARS-CoV-2 Omicron infection: a cohort study.
Clin Infect Dis. 2024 Dec 5:ciae598. doi: 10.1093. PubMedAbstract available
TENFORDE MW, Reeves EL, Weber ZA, Tartof SY, et al Influenza vaccine effectiveness against hospitalizations and emergency department
or urgent care encounters for children, adolescents, and adults during the
2023-2024 season, United States.
Clin Infect Dis. 2024 Dec 4:ciae597. doi: 10.1093. PubMedAbstract available
November 2024
TOWNSEND JP, Hassler HB, Dornburg A Optimal Annual COVID-19 Vaccine Boosting Dates Following Previous Booster
Vaccination or Breakthrough Infection.
Clin Infect Dis. 2024 Nov 26:ciae559. doi: 10.1093. PubMedAbstract available
CHOKEPHAIBULKIT K, Huoi C, Tantawichien T, Mootsikapun P, et al Non-inferiority study of purified Vero rabies vaccine - serum free in three-dose
and two-dose pre-exposure prophylaxis regimens in comparison with licensed rabies
vaccines.
Clin Infect Dis. 2024 Nov 26:ciae581. doi: 10.1093. PubMedAbstract available
Correction to: Immunogenicity, Safety, and Efficacy of a Tetravalent Dengue
Vaccine in Children and Adolescents: An Analysis by Age Group.
Clin Infect Dis. 2024 Nov 15:ciae504. doi: 10.1093. PubMed
Correction to: Development of an Effective Immune Response in Adults With Down
Syndrome After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Vaccination.
Clin Infect Dis. 2024 Nov 15:ciae506. doi: 10.1093. PubMed
DAVIS M, Towner W, DeHaan E, Jiang Q, et al Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk Conditions.
Clin Infect Dis. 2024 Nov 11:ciae550. doi: 10.1093. PubMedAbstract available
ROGERS JH, Westley B, Mego T, Newell KG, et al Fatal borealpox in an immunosuppressed patient treated with antivirals and
vaccinia immunoglobulin - Alaska, 2023.
Clin Infect Dis. 2024 Nov 5:ciae536. doi: 10.1093. PubMedAbstract available
VAN DER STAAK M, Ten Hulscher HI, Nicolaie AM, Smits GP, et al Long-term dynamics of measles virus-specific neutralizing antibodies in children
vaccinated before 12 months of age.
Clin Infect Dis. 2024 Nov 4:ciae537. doi: 10.1093. PubMedAbstract available
October 2024
WHITE EB, Grant L, Mak J, Olsho L, et al Influenza Vaccine Effectiveness Against Illness and Asymptomatic Infection in
2022-2023: A Prospective Cohort Study.
Clin Infect Dis. 2024 Oct 24:ciae491. doi: 10.1093. PubMedAbstract available
TAN SK, Cebrik D, Plotnik D, Agostini ML, et al A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of
VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA).
Clin Infect Dis. 2024;79:1054-1061. PubMedAbstract available
SELF WH, Johnson KD, Resser JJ, Whitney CG, et al Prevalence, Clinical Severity, and Serotype Distribution of Pneumococcal
Pneumonia Among Adults Hospitalized With Community-Acquired Pneumonia in
Tennessee and Georgia, 2018-2022.
Clin Infect Dis. 2024;79:838-847. PubMedAbstract available
BEGLEY KM, Leis AM, Petrie JG, Truscon R, et al Epidemiology of Respiratory Syncytial Virus in Adults and Children With Medically
Attended Acute Respiratory Illness Over Three Seasons.
Clin Infect Dis. 2024;79:1039-1045. PubMedAbstract available
MONTANO M, Shapiro AE, Whitney BM, Bamford L, et al Mpox in People With Human Immunodeficiency Virus: Predictors of Diagnosis,
Outcomes, and Vaccine Effectiveness in a Multisite Cohort.
Clin Infect Dis. 2024 Oct 8:ciae464. doi: 10.1093. PubMedAbstract available
September 2024
FONG Y, Dang L, Zhang B, Fintzi J, et al Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the
COVAIL Trial.
Clin Infect Dis. 2024 Sep 26:ciae465. doi: 10.1093. PubMedAbstract available
LEUNG J, Munir NA, Mathis AD, Filardo TD, et al The Effects of Vaccination Status and Age on Clinical Characteristics and
Severity of Measles Cases in the United States in the Post-Elimination Era,
2001-2022.
Clin Infect Dis. 2024 Sep 13:ciae470. doi: 10.1093. PubMedAbstract available
PLOTKIN SA, Robinson JM, Fitchett JRA, Gershburg E, et al Vaccine Development Should Be Polytheistic, Not Monotheistic.
Clin Infect Dis. 2024 Sep 6:ciae460. doi: 10.1093. PubMedAbstract available
August 2024
Correction to: Pivotal Phase 3 Randomized Clinical Trial of the Safety,
Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in
Adults Aged >/=18 Years.
Clin Infect Dis. 2024 Aug 29:ciae389. doi: 10.1093. PubMed
Correction to: Immunogenicity and Safety of a Purified Vero Rabies Vaccine-Serum
Free, Compared With 2 Licensed Vaccines, in a Simulated Rabies Post-Exposure
Regimen in Healthy Adults in France: A Randomized, Controlled, Phase 3 Trial.
Clin Infect Dis. 2024 Aug 28:ciae390. doi: 10.1093. PubMed
DONSKEY CJ, Dubberke ER, Klein NP, Liles EG, et al CLOVER: A Phase 3 Randomized Trial Investigating the Efficacy and Safety of a
Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of
Clostridioides difficile Infection.
Clin Infect Dis. 2024 Aug 24:ciae410. doi: 10.1093. PubMedAbstract available
KUIJPER EJ, Gerding DN The end of toxoid vaccine development for preventing Clostridioides difficile
infections?
Clin Infect Dis. 2024 Aug 24:ciae412. doi: 10.1093. PubMed
KU JH, Rayens E, Sy LS, Qian L, et al Comparative Effectiveness of Licensed Influenza Vaccines in Preventing
Influenza-related Medical Encounters and Hospitalizations in the 2022-2023
Influenza Season Among Adults >/=65 Years of Age.
Clin Infect Dis. 2024 Aug 21:ciae375. doi: 10.1093. PubMedAbstract available
BERTHAUD V, Creech CB, Rostad CA, Carr Q, et al Safety and Immunogenicity of an mRNA-1273 Booster in Children.
Clin Infect Dis. 2024 Aug 19:ciae420. doi: 10.1093. PubMedAbstract available
JAYASINGHE S, Williams PCM, Macartney KK, Crawford NW, et al Assessing the Impact of Pneumococcal Conjugate Vaccine Immunization Schedule
Change From 3+0 to 2+1 in Australian Children: A Retrospective Observational
Study.
Clin Infect Dis. 2024 Aug 14:ciae377. doi: 10.1093. PubMedAbstract available
MA KC, Surie D, Lauring AS, Martin ET, et al Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination
Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a
Comparison of Clinical Severity-IVY Network, 26 Hospitals, October 18, 2023-March
9, 2024.
Clin Infect Dis. 2024 Aug 6:ciae405. doi: 10.1093. PubMedAbstract available
FERGUSON M, Schwarz TF, Nunez SA, Rodriguez-Garcia J, et al Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus
Prefusion F Protein Vaccine in Adults 50-59 Years Compared to >/=60 Years of Age.
Clin Infect Dis. 2024 Aug 5:ciae364. doi: 10.1093. PubMedAbstract available
CLARK R, Davies S, Labrador J, Loubet P, et al Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein
Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza
Vaccine in Older Adults: A Phase 3 Randomized Trial.
Clin Infect Dis. 2024 Aug 5:ciae365. doi: 10.1093. PubMedAbstract available
BRANCHE AR We Have Effective Respiratory Syncytial Virus Vaccines to Prevent Disease in
Adults: What Else Do We Need to Know About How to Use Them?
Clin Infect Dis. 2024 Aug 5:ciae362. doi: 10.1093. PubMed
July 2024
SCOTT P, Haranaka M, Choi JH, Stacey H, et al A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity
of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older
(Stride-6).
Clin Infect Dis. 2024 Jul 31:ciae383. doi: 10.1093. PubMedAbstract available
COWLING BJ, Wong SS, Santos JJS, Touyon L, et al Preliminary findings from the Dynamics of the Immune Responses to Repeat
Influenza Vaccination Exposures (DRIVE I) Study: a Randomized Controlled Trial.
Clin Infect Dis. 2024 Jul 23:ciae380. doi: 10.1093. PubMedAbstract available
EDOSA M, Jeon Y, Gedefaw A, Hailu D, et al Comprehensive Review on the Use of Oral Cholera Vaccine (OCV) in Ethiopia: 2019
to 2023.
Clin Infect Dis. 2024;79. PubMedAbstract available
HUSSEN M, Worku Demlie Y, Edosa M, Kebede M, et al Ethiopia National Cholera Elimination Plan 2022-2028: Experiences, Challenges,
and the Way Forward.
Clin Infect Dis. 2024;79. PubMedAbstract available
PARK SE, Gedefaw A, Hailu D, Jeon Y, et al Coverage of Two-Dose Preemptive Cholera Mass Vaccination Campaign in
High-Priority Hotspots in Shashemene, Oromia Region, Ethiopia.
Clin Infect Dis. 2024;79. PubMedAbstract available
BORJA-TABORA C, Fernando L, Lopez Medina E, Reynales H, et al Immunogenicity, safety, and efficacy of a tetravalent dengue vaccine in children
and adolescents: an analysis by age group.
Clin Infect Dis. 2024 Jul 12:ciae369. doi: 10.1093. PubMedAbstract available
JOHNSTON TS, Hage C, Abedon AT, Panda S, et al Rapid Wane and Recovery of XBB Sublineage Neutralization After Sequential
Omicron-based Vaccination in Solid Organ Transplant Recipients.
Clin Infect Dis. 2024 Jul 2:ciae279. doi: 10.1093. PubMedAbstract available
June 2024
CHONG C, Wee LE, Jin X, Zhang M, et al Risks of SARS-CoV-2 JN.1 infection and COVID-19 associated emergency-department
(ED) visits/hospitalizations following updated boosters and prior infection: a
population-based cohort study.
Clin Infect Dis. 2024 Jun 26:ciae339. doi: 10.1093. PubMedAbstract available
RUSS RK, Vandehei HM, Golovkina MI, Mogallapalli H, et al Hepatitis B-CpG vaccine series for healthcare workers who are hepatitis B vaccine
nonresponders.
Clin Infect Dis. 2024 Jun 17:ciae320. doi: 10.1093. PubMedAbstract available
BOECKH M, Pergam SA, Limaye AP, Englund J, et al How Immunocompromised Hosts Were Left Behind in the Quest to Control the Covid-19
Pandemic.
Clin Infect Dis. 2024 Jun 3:ciae308. doi: 10.1093. PubMedAbstract available
May 2024
WOLFE DN, Arangies E, David GL, Armstrong B, et al Development of Next-Generation COVID-19 Vaccines: BARDA Supported Phase 2b Study
Designs.
Clin Infect Dis. 2024 May 28:ciae286. doi: 10.1093. PubMedAbstract available
HILL JA, Martens MJ, Young JH, Bhavsar K, et al SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or
chimeric antigen receptor T cell therapy: A prospective, multicenter,
observational study.
Clin Infect Dis. 2024 May 27:ciae291. doi: 10.1093. PubMedAbstract available
JORGENSEN SCJ, Brown K, Clarke AE, Schwartz KL, et al The Effect of COVID-19 Vaccination on Outpatient Antibiotic Prescribing in Older
Adults: A Self-Controlled Risk-Interval Study.
Clin Infect Dis. 2024 May 3:ciae182. doi: 10.1093. PubMedAbstract available
April 2024
Correction to: Impact of Seasonal Coronavirus Antibodies on Severe Acute
Respiratory Syndrome Coronavirus 2 Vaccine Responses in Solid Organ Transplant
Recipients.
Clin Infect Dis. 2024 Apr 30:ciae164. doi: 10.1093. PubMed
MWESIGWA B, Sawe F, Oyieko J, Mwakisisile J, et al Safety and Immunogenicity of Accelerated Heterologous Two-dose Ebola Vaccine
Regimens in Adults With and Without HIV in Africa.
Clin Infect Dis. 2024 Apr 24:ciae215. doi: 10.1093. PubMedAbstract available
HASAN T, Lynch M, King C, Wehbe C, et al Vaccine-Preventable Disease Outbreaks among Healthcare Workers: A Scoping Review.
Clin Infect Dis. 2024 Apr 17:ciae209. doi: 10.1093. PubMedAbstract available
Correction to: Discordant Antibody and T-Cell Responses to the Severe Acute
Respiratory Syndrome Coronavirus 2 Omicron Variant in Coronavirus Disease 2019
Messenger RNA Vaccine Recipients.
Clin Infect Dis. 2024 Apr 15:ciae165. doi: 10.1093. PubMed
SHERMAN A, Tuan J, Cantos VD, Adeyiga O, et al COVID-19 vaccine efficacy in participants with weakened immune systems from four
randomized-controlled trials.
Clin Infect Dis. 2024 Apr 10:ciae192. doi: 10.1093. PubMedAbstract available
FAHERTY EAG, Holly T, Ogale YP, Spencer H, et al Investigation of an mpox outbreak affecting many vaccinated persons in Chicago,
IL-March 2023-June 2023.
Clin Infect Dis. 2024 Apr 3:ciae181. doi: 10.1093. PubMedAbstract available
SU WJ, Chen HL, Chen SF, Liu YL, et al Optimization of Mother-to-Child Hepatitis B Virus Prevention Program: Integration
of Maternal Screening and Infant Post-vaccination Serologic Testing.
Clin Infect Dis. 2024 Apr 2:ciae176. doi: 10.1093. PubMedAbstract available
March 2024
ROSTAD CA, Atmar RL, Walter EB, Frey S, et al A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and
Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017
A(H7N9) Inactivated Influenza Virus Vaccines Administered with and without AS03
Adjuvant in Healthy US
Clin Infect Dis. 2024 Mar 27:ciae173. doi: 10.1093. PubMedAbstract available
PINEDA-PENA AC, Jiang Q, Petit C, Korejwo-Peyramond J, et al Immunogenicity and Safety of a Purified Vero Rabies Vaccine - Serum Free,
Compared With Two Licensed Vaccines, in a Simulated Rabies Post-Exposure Regimen
in Healthy Adults in France: A Randomized Controlled Phase III Trial.
Clin Infect Dis. 2024 Mar 13:ciae137. doi: 10.1093. PubMedAbstract available
SHRESTHA NK, Burke PC, Nowacki AS, Gordon SM, et al Effectiveness of the 2023-2024 Formulation of the Coronavirus Disease 2019 mRNA
Vaccine.
Clin Infect Dis. 2024 Mar 11:ciae132. doi: 10.1093. PubMedAbstract available
ROMINE JK, Li H, Coughlin MM, Jones JM, et al Hybrid immunity and SARS-CoV-2 antibodies: results of the HEROES-RECOVER
prospective cohort study.
Clin Infect Dis. 2024 Mar 11:ciae130. doi: 10.1093. PubMedAbstract available
February 2024
SHAH MM, Joyce B, Plumb ID, Sahakian S, et al Combined protection of vaccination and nirmatrelvir-ritonavir against
hospitalization in adults with COVID-19.
Clin Infect Dis. 2024 Feb 27:ciae105. doi: 10.1093. PubMedAbstract available
December 2023
THOMAS LD, Batarseh E, Hamdan L, Haddadin Z, et al Comparison of Two High-Dose Versus Two Standard-Dose Influenza Vaccines in Adult
Allogeneic Hematopoietic Cell Transplant Recipients.
Clin Infect Dis. 2023;77:1723-1732. PubMedAbstract available
RYBAK A, Assad Z, Levy C, Bonarcorsi S, et al Age-specific resurgence in invasive pneumococcal disease incidence in the
COVID-19 pandemic era and its association with respiratory virus and pneumococcal
carriage dynamics: a time series analysis.
Clin Infect Dis. 2023 Dec 6:ciad746. doi: 10.1093. PubMedAbstract available
November 2023
USDAN L, Patel S, Rodriguez H, Xu X, et al A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in >/=12-Year-Olds.
Clin Infect Dis. 2023 Nov 28:ciad718. doi: 10.1093. PubMedAbstract available